National Mar 11, 2022
The emergence of the omicron variant, which usually causes milder infections, made it tough to determine the drug's effectiveness in preventing severe symptoms, the company said.
The emergence of the omicron variant, which usually causes milder infections, made it tough to determine the drug's effectiveness in preventing severe symptoms, the company said.
U.S. man with transplanted genetically modified pig heart dies
The patient, David Bennett, "wasn't able to overcome what turned out to be the devastating debilitation" caused by the heart failure he experienced before the transplant.
The humble cough drop could be used to map omicron’s spread
Soaring sales of lozenges, gargles and other over-the-counter medication has squeezed supplies — even in countries where cases are falling.
Crispr might actually live up to its immense hype
The Nobel prize-winning technology is moving from a concept to the clinic at a breathtaking pace.
Hong Kong is battling its worst wave yet of COVID-19, which is claiming the lives of at least a hundred people a day.
Shionogi says its COVID-19 shot is effective and safe
The positive data could mean Japan, which is racing to complete a booster drive in hopes of curbing future outbreaks, will soon have an indigenous jab.
Shionogi seeks approval for Japan’s first domestic COVID pill
Kishida has signaled that the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed.
Medical experts in Japan concerned that omicron symptoms will be mistaken for hay fever
This year’s hay fever season has arrived amid the spread of the omicron variant, which often leads to similar symptoms, such as sneezing and a running nose.
In an ‘age of pandemics,’ pathogen-sharing can't be optional
No one country should be free to hold essential data and pathogens hostage in the name of securing their own benefit at the cost of global public health.
New COVID-19 variants complicate the question of vaccine mandates
Officials mulling new pandemic policies need to know how quickly vaccine protection wanes. But scientists don't have a clear answer.
These vaccines have been embraced by the world. Why not in China?
Two years into the pandemic, China’s 1.4 billion people still don’t have access to one of the most effective coronavirus vaccines the world has to offer.
Investments in health systems will protect human security now, and into the future
COVID-19 has exposed the deep inequities and weaknesses in the global health system.